Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Piper Sandler Maintains Overweight on Paycom Software, Raises Price Target to $417

Piper Sandler analyst Arvind Ramnani maintains Paycom Software (NYSE:PAYC) with a Overweight and raises the price target from $395 to $417.

byBenzinga Newsdesk

February 8, 2023

1 minute read

Piper Sandler analyst Arvind Ramnani maintains Paycom Software (NYSE:PAYC) with a Overweight and raises the price target from $395 to $417.

Digital World Acquisition Corp Is By Far The Most Shorted SPAC: The Other Top SPACs Short Sellers Are Targeting

By Wayne Duggan

Today, 5:24 AM

Digital World Acquisition Corp (NASDAQ: DWAC) shares plunged 20.1% on Wednesday morning after Republican candidates endorsed by President Donald Trump performed poorly

ALTU

Southern National Bancorp Q2 EPS $0.42 Up From $0.19 YoY

By Benzinga Newsdesk

Today, 5:24 AM

Southern National Bancorp (NASDAQ:FRST) reported quarterly earnings of $0.42 per share. This is a 121.05 percent increase over earnings of $0.19 per share from the same period last year.

FRST

UPDATE: UK’s Medicines and Healthcare products Regulatory Agency Says Data For Neutralizing Antibodies Of Pfizer/BioNTech’s COVID-19 Vaccine Work At Same Levels As Seen In Adults Aged 16-25 Years

By Benzinga Newsdesk

Today, 5:24 AM

-Reuters

BNTX

Credit Suisse Downgrades Cinemark Hldgs to Underperform, Lowers Price Target to $9

By Benzinga Newsdesk

Today, 5:24 AM

Credit Suisse analyst Douglas Mitchelson downgrades Cinemark Hldgs (NYSE:CNK) from Outperform to Underperform and lowers the price target from $25 to $9.

CNK

Piper Sandler Maintains Overweight on Paycom Software, Raises Price Target to $417

Related Posts

Digital World Acquisition Corp Is By Far The Most Shorted SPAC: The Other Top SPACs Short Sellers Are Targeting

Southern National Bancorp Q2 EPS $0.42 Up From $0.19 YoY

UPDATE: UK’s Medicines and Healthcare products Regulatory Agency Says Data For Neutralizing Antibodies Of Pfizer/BioNTech’s COVID-19 Vaccine Work At Same Levels As Seen In Adults Aged 16-25 Years

Credit Suisse Downgrades Cinemark Hldgs to Underperform, Lowers Price Target to $9